ID: ALA5191378

Max Phase: Preclinical

Molecular Formula: C42H60N8O9S2

Molecular Weight: 885.12

Associated Items:

Representations

Canonical SMILES:  CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]2CCCN2)CSCc2cccc(n2)CSC[C@@H](C(=O)O)NC(=O)[C@H](C)NC1=O

Standard InChI:  InChI=1S/C42H60N8O9S2/c1-23(2)16-31-38(54)44-25(5)36(52)50-35(42(58)59)22-61-20-28-9-6-8-27(45-28)19-60-21-34(49-37(53)30-10-7-15-43-30)41(57)47-32(17-24(3)4)39(55)48-33(40(56)46-31)18-26-11-13-29(51)14-12-26/h6,8-9,11-14,23-25,30-35,43,51H,7,10,15-22H2,1-5H3,(H,44,54)(H,46,56)(H,47,57)(H,48,55)(H,49,53)(H,50,52)(H,58,59)/t25-,30-,31-,32-,33-,34-,35-/m0/s1

Standard InChI Key:  METYKGYVFSESFD-PTQLHCGHSA-N

Associated Targets(Human)

Kallikrein 7 657 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 885.12Molecular Weight (Monoisotopic): 884.3925AlogP: 1.37#Rotatable Bonds: 9
Polar Surface Area: 257.05Molecular Species: ZWITTERIONHBA: 12HBD: 9
#RO5 Violations: 3HBA (Lipinski): 17HBD (Lipinski): 9#RO5 Violations (Lipinski): 3
CX Acidic pKa: 3.54CX Basic pKa: 9.80CX LogP: -1.26CX LogD: -1.26
Aromatic Rings: 2Heavy Atoms: 61QED Weighted: 0.17Np Likeness Score: 0.68

References

1. Gonschorek P, Zorzi A, Maric T, Le Jeune M, Schüttel M, Montagnon M, Gómez-Ojea R, Vollmar DP, Whitfield C, Reymond L, Carle V, Verma H, Schilling O, Hovnanian A, Heinis C..  (2022)  Phage Display Selected Cyclic Peptide Inhibitors of Kallikrein-Related Peptidases 5 and 7 and Their In Vivo Delivery to the Skin.,  65  (14.0): [PMID:35653695] [10.1021/acs.jmedchem.2c00306]

Source